Nephros (NEPH) Income from Continuing Operations (2010 - 2026)
Nephros' (NEPH) quarterly Income from Continuing Operations came in at 29000.0 in Q1 2026, up 103.23% year-on-year from 14269.84 in Q1 2025, and down 53.23% quarter-over-quarter from 62000.0 in Q4 2025.
Nephros (NEPH) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Nephros' Income from Continuing Operations history runs 17 years deep, the most recent figure standing at 29000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 103.23% year-over-year to 29000.0 in Q1 2026; TTM through Mar 2026 was 665000.0, a 203.74% increase from a year earlier, with the FY2025 full-year figure at 1194000.0, up 1513.51% from the prior year.
- Income from Continuing Operations retreated to 29000.0 in Q1 2026 per NEPH's latest filing, from 62000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 364000.0 in Q4 2024 and bottomed at 1721000.0 in Q3 2022.
- The 5-year median for Income from Continuing Operations is 440000.0 (2023), against an average of 456529.41.
- Across the five-year window, Income from Continuing Operations jumped 182.73% in 2024 and slumped 332.21% in 2025, its largest moves.
- Year by year, Income from Continuing Operations stood at 689000.0 in 2022, then surged by 36.14% to 440000.0 in 2023, then soared by 182.73% to 364000.0 in 2024, then slumped by 82.97% to 62000.0 in 2025, then plunged by 53.23% to 29000.0 in 2026.
- Per Business Quant, the three latest NEPH Income from Continuing Operations figures stand at 29000.0 (Q1 2026), 62000.0 (Q4 2025), and 337000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 33,163,703.85 Bn | 33,163,702.19 Bn | 1.53 Bn | 240.00 Mn |
| 2 | Intuitive Surgical | 119.67 Bn | 114.45 Bn | 1.96 Bn | 823.20 Mn |
| 3 | Becton Dickinson | 43.92 Bn | 43.11 Bn | 2.15 Bn | -37.00 Mn |
| 4 | Medline | 31.71 Bn | 29.47 Bn | 1.84 Bn | 239.00 Mn |
| 5 | Resmed | 28.46 Bn | 26.80 Bn | 890.98 Mn | 398.73 Mn |
| 6 | West Pharmaceutical Services | 23.80 Bn | 23.28 Bn | 296.40 Mn | 135.40 Mn |
| 7 | Cooper Companies | 13.77 Bn | 13.63 Bn | 735.40 Mn | -77.90 Mn |
| 8 | Solventum | 13.63 Bn | 13.06 Bn | 1.10 Bn | 13.00 Mn |
| 9 | Align Technology | 11.94 Bn | 10.88 Bn | 736.59 Mn | 112.77 Mn |
| 10 | Nephros | 38.82 Mn | 34.80 Mn | 2.99 Mn | 29,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 29,000.00 |
| Dec 31, 2025 | 62,000.00 |
| Sep 30, 2025 | 337,000.00 |
| Jun 30, 2025 | 237,000.00 |
| Mar 31, 2025 | -899,000.00 |
| Dec 31, 2024 | 364,000.00 |
| Sep 30, 2024 | 183,000.00 |
| Jun 30, 2024 | -289,000.00 |
| Mar 31, 2024 | -208,000.00 |
| Dec 31, 2023 | -440,000.00 |
| Sep 30, 2023 | -1.03 Mn |
| Jun 30, 2023 | -590,000.00 |
| Mar 31, 2023 | -462,000.00 |
| Dec 31, 2022 | -689,000.00 |
| Sep 30, 2022 | -1.72 Mn |
| Jun 30, 2022 | -955,000.00 |
| Mar 31, 2022 | -1.69 Mn |
| Dec 31, 2021 | -726,000.00 |
| Sep 30, 2021 | -883,000.00 |
| Jun 30, 2021 | -1.15 Mn |